Drugs / KB707
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06228326 | Apr 2024 → Feb 2027 expected | non-small cell lung carcinoma | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05970497 | Oct 2023 → Jul 2027 expected | cutaneous melanoma | Krystal Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KB707 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05970497 ↗ |
| Route | Other | “Subjects in dose escalation (Cohorts 1 through 3) and dose expansion (Cohort 4) will receive intratumoral injections of KB707 approximately every three weeks” NCT05970497 ↗ |